血液公司
US ˙ NYSE ˙ US4050241003

SecurityHAE / Haemonetics Corporation
InstitutionElkfork Partners LLC
Latest Disclosed Ownership7,920 shares
Latest Disclosed Value $ 999,000
Elkfork Partners LLC reports 3.45% increase in ownership of HAE / Haemonetics Corporation

On November 14, 2019 - Elkfork Partners LLC filed a 13F-HR form disclosing ownership of 7,920 shares of Haemonetics Corporation (US:HAE) valued at $999,029 USD as of September 30, 2019. The entity filed a previous 13F-HR on August 13, 2019 disclosing 7,656 shares of Haemonetics Corporation. This represents a change in shares of 3.45% during the quarter. The current value of the position is $564,538 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2019-11-14 2019-09-30 13F Haemonetics COM 405024100 7,920 264 3.45 999 8.47 0.0243
2019-08-13 2019-06-30 13F Haemonetics COM 405024100 7,656 0 0.00 921 37.46 0.0225
2019-05-13 2019-03-31 13F Haemonetics COM 405024100 7,656 264 3.57 670 -9.46 0.0168
2019-02-13 2018-12-31 13F Haemonetics COM 405024100 7,392 0 0.00 740 -12.63 0.0209
2018-11-14 2018-09-30 13F Haemonetics COM 405024100 7,392 1,628 28.24 847 63.83 0.0201
2018-08-13 2018-06-30 13F Haemonetics COM 405024100 5,764 0 0.00 517 22.51 0.0133
2018-05-10 2018-03-31 13F Haemonetics COM 405024100 5,764 0 0.00 422 25.97 0.0114
2018-02-24 2017-12-31 13F/A-1 Haemonetics COM 405024100 5,764 990 20.74 335 56.54 0.0091
2018-02-22 2017-12-31 13F Haemonetics COM 405024100 4,192 -582 243
2017-11-14 2017-09-30 13F Haemonetics COM 405024100 4,774 484 11.28 214 26.63 0.0062
2017-08-14 2017-06-30 13F Haemonetics COM 405024100 4,290 1,980 85.71 169 79.79 0.0051
2017-05-03 2017-03-31 13F Haemonetics COM 405024100 2,310 0 0.00 94 1.08 0.0029
2017-02-10 2016-12-31 13F Haemonetics COM 405024100 2,310 2,310 93 0.0031
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.